ClinicalTrials.gg
Not yet recruitingNCT07728955SCLCUpdated Jul 27, 2026

A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy

A Phase 3 interventional study of benmelstobart in combination with anlotinib and etoposide in Small Cell Lung Cancer ( SCLC ), sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing benmelstobart in Small Cell Lung Carcinoma — 8 open to participants now, 8 under way, 2 of them phase 3. benmelstobart · Small Cell Lung Carcinoma.

Planned enrollment
4th of 10
64 · median 45
Started
2026
with 2 others
Phase 3
3 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 10 studies testing benmelstobart in Small Cell Lung Carcinoma, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 3, and was the 10th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

8 of the 10 studies testing benmelstobart in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About benmelstobart

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing benmelstobart in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

A single-arm exploratory clinical study to observe and evaluate the first-line treatment of elderly and treatment-intolerant patients with small cell lung cancer using benmelstobart in combination with anlotinib and etoposide.

Eligible patients are those with histologically or pathologically confirmed small cell lung cancer (SCLC) (AJCC 9th edition), who are treatment-naïve and considered elderly or intolerant to intensive therapy. Eligible subjects receive 4-6 cycles of benmelstobart injection combined with anlotinib hydrochloride and etoposide, followed by maintenance therapy with benmelstobart injection plus anlotinib hydrochloride, continued until disease progression or intolerable toxicity.

The study aims to evaluate the efficacy and safety of first-line treatment with benmelstobart injection in combination with anlotinib hydrochloride and etoposide in patients with advanced SCLC.

03

Conditions studied

  • Small Cell Lung Cancer ( SCLC )
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must voluntarily participate in this study after being fully informed and must sign a written form (ICF), and be willing and able to comply with the study procedures and requirements.
  2. At the time of signing the ICF, male or female subjects aged ≥65 years, or male or female subjects aged ≥18 years who are assessed by the investigator as not suitable for intensive treatment, defined as: performance status of 2-3, or comorbidities (CIRS >6 and ≤12), or otherwise judged by the investigator as not suitable for intensive treatment. Intensive treatment is defined as intensive therapy for small cell lung cancer, i.e., standard chemotherapy with etoposide plus cisplatin or carboplatin combined with and targeted agents.
  3. or cytologically confirmed metastatic small cell lung cancer (SCLC), according to the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer TNM staging system, 9th edition (AJCC 9th).
  4. Subjects must not have received prior systemic therapy for metastatic SCLC. Patients who previously received adjuvant, , or radical chemoradiotherapy for non-metastatic disease are eligible if disease progression occurred >6 months after completion of the last treatment.
  5. At least one measurable target lesion according to v1.1. Lesions previously treated with radiotherapy or other local regional therapy are not considered target lesions unless clear progression is documented after treatment. Lesions must have a longest diameter ≥10 mm on CT or MRI at baseline (lymph nodes must have a short axis ≥15 mm), and must be suitable for repeated accurate measurement per RECIST v1.1.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.
  7. Adequate organ function as defined below, with no blood transfusion or use of hematopoietic growth factors within 14 days prior to testing: (PLT) ≥80 × 10⁹/L (HGB) ≥80 g/L Neutrophils (NEUT) ≥1.5 × 10⁹/L Creatinine ≤1.5 × (ULN) or (CrCl) ≥30 mL/min (Cockcroft-Gault) and AST ≤2.5 × ULN (≤5 × ULN if liver metastases present) Total (TBIL) ≤1.5 × ULN (≤3 × ULN in Gilbert's syndrome) or PT ≤1.5 × ULN and APTT ≤1.5 × ULN, or clinically acceptable bleeding risk as assessed by investigator Urine protein \<2+ or 24-hour urine protein \<1 g Expected survival ≥3 months Women of must agree to use effective during and for 6 months after the study and have a negative serum pregnancy test within 7 days before enrollment and must not be breastfeeding Male subjects must agree to use effective contraception during and for 6 months after the study Willingness to participate and good compliance with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Prior anti-cancer therapy within specified time windows: Anti-/PD-L1 therapy within 3 years before first dose Anti-angiogenic multi-target TKIs (e.g., anlotinib, apatinib) within 3 years Any anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy, etc.) or drug within 28 days before first dose Traditional Chinese medicines with approved anti-cancer indications within 2 weeks before first dose (e.g., Fufang Banmao capsule, Kang'ai injection, Kanglaite capsule/injection, Aidi injection, Yadanzi oil injection/capsule, Xiaoaiping tablets/injection, Huachansu capsule, etc.)
  2. Other primary , except: Tumors treated by single surgery with complete remission ≥3 years before enrollment Non-melanoma skin cancer or in situ cancers not requiring treatment Prostate cancer requiring only clinical observation
  3. Symptomatic or progressing or carcinomatous meningitis. Patients with stable brain metastases may be eligible if: No neurological symptoms No use required and no indication for radiotherapy Largest brain lesion ≤1.5 cm Stable on two brain MRI/CT scans ≥2 weeks apart Additional timing and stability conditions after CNS treatment as specified Off corticosteroids ≥2 weeks if previously treated with CNS radiotherapy ≥4 weeks interval after CNS surgery before first dose
  4. Cardiovascular conditions including: class II or higher heart failure Severe arrhythmia requiring treatment Myocardial infarction, unstable angina, or vascular bypass within 6 months \<40% prolongation (female >470 ms, male >450 ms) or risk factors for torsades de pointes Uncontrolled hypertension (SBP ≥150 mmHg and/or DBP ≥100 mmHg despite treatment)
  5. Thrombotic events within 6 months (e.g., stroke, , DVT, pulmonary embolism), hypertensive crisis, or encephalopathy.
  6. History of epilepsy.
  7. Superior vena cava syndrome.
  8. Active or uncontrolled pulmonary conditions including interstitial lung disease, radiation pneumonitis, immune-related pneumonitis, active tuberculosis, pneumoconiosis, or severe pulmonary impairment (, DLCO, or DLCO/VA \<40%).
  9. Severe bone -related complications (e.g., pathological fracture, spinal cord compression, uncontrolled bone pain).
  10. Active uncontrolled infection (≥ grade 2) or fever >38.5°C of unknown cause.
  11. Uncontrolled third-space fluid accumulation (pleural, peritoneal, pericardial effusion), unless stable after drainage.
  12. Tumor invasion or unclear boundary with major blood vessels on imaging.
  13. Bleeding tendency within 2 months or hemoptysis (>2.5 mL/day) within 2 weeks, or unhealed wounds/ulcers/fractures.
  14. Significant gastrointestinal disease affecting drug absorption (e.g., severe ulcers, cirrhosis, bowel obstruction, IBD, surgery affecting absorption, etc.).
  15. within 4 weeks before first dose.
  16. Severe to monoclonal antibody therapies.
  17. Active disease requiring systemic therapy within 2 years (excluding replacement therapies).
  18. Immunodeficiency or ongoing therapy (>10 mg/day prednisone equivalent) within 2 weeks before dosing.
  19. positivity, active or C infection as defined by HBV DNA or thresholds.
  20. Active syphilis, dialysis-dependent renal failure.
  21. Poorly controlled diabetes (fasting glucose >10 mmol/L).
  22. History of organ transplantation or planned transplantation.
  23. Major surgery or significant trauma within 4 weeks before first dose.
  24. Palliative radiotherapy within 2 weeks before first dose.
  25. Unresolved prior treatment toxicities (except alopecia/pigmentation/lab abnormalities not ); peripheral neuropathy not recovered to ≤Grade 2.
  26. Pregnancy or breastfeeding.
  27. Severe psychiatric illness, drug abuse, or alcoholism.
  28. Known allergy to study drug or any of its components.
  29. Any other clinically significant condition that may compromise safety or interfere with study assessments as judged by the investigator.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug: benmelstobart in combination with anlotinib and etoposide

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: From first dose of study treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.

Secondary outcomes

  1. Objective Response Rate(ORR)

    ORR is defined as the percentage of participants with a confirmed Complete Response (CR) or Partial Response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Through study completion, an average of 1 year.

  2. Disease Control Rate (DCR)

    Time frame: Through study completion, an average of 1 year.

  3. Duration of Response (DoR)

    Time frame: From the date of first documented response (CR or PR) until the date of first documented disease progression or death, whichever came first, assessed up to 24 months.

  4. Overall Survival (OS)

    Time frame: From first dose of study treatment until date of death from any cause, assessed up to 36 months.

  5. Safety and Tolerability

    Safety will be evaluated by summarizing the incidence of AEs, irAEs, and SAEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v6.0.

    Time frame: From first dose of study treatment until 30 days after last dose, assessed up to 24 months.

  6. Cancer-Specific Survival (CSS)

    Time frame: From first dose of study treatment until date of death due to small cell lung cancer , assessed up to 36 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

Of 68 phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 48. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 27, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Aug 31, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07728955
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Heping Li
Contact
liheping@mail.sysu.edu.cn
+86 13710873975
Xiuxing Chen
Contact
Chenxx266@mail.sysu.edu.cn
+86 13265129905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Anlotinib · Etoposide

Start the discussion